In a nutshell This study investigated the safety and effectiveness of intermittent fasting (IF) for 3 non-consecutive days a week, over a period of 12 weeks in people with insulin-treated type 2 diabetes (T2D). The authors concluded that this dietary approach was safe and effective for controlling blood glucose, reducing total daily insulin requirements,...
Read More
In a nutshell This review assessed the effectiveness and safety of ultra-rapid insulin analogs (URIAs) with continuous subcutaneous insulin systems (CSII) in adults with type 1 diabetes (T1D). The authors concluded that URIAs were compatible with CSII systems and had a better glucose-lowering effect after meals compared to rapid-acting insulin...
Read More
In a nutshell This study evaluated the most effective and safe dose of dapagliflozin (Farxiga) as an additional treatment to insulin in patients with type 1 diabetes (T1D). The authors concluded that 10 mg of dapagliflozin as an add-on to insulin treatment resulted in improved blood glucose (sugar) control, reduced insulin dosage, and body...
Read More
In a nutshell This study assessed the effectiveness and safety of adding metformin (Glucophage) to insulin therapy in the treatment of adolescents with type 1 diabetes (T1D). The study showed that the use of metformin in these patients resulted in improved blood glucose control and body mass index (BMI) with an increased risk of...
Read More
In a nutshell This study compared the effectiveness and safety of biphasic insulin aspart 30 (BIAsp 30; NovoMix 30) alone or with metformin (Glucophage), in patients with inadequately controlled type 2 diabetes (T2D). The authors concluded that combined therapy may be preferred in patients with high cardiovascular risk and/or a body...
Read More
In a nutshell This study compared the safety and effectiveness of liraglutide (Victoza) to insulin glargine (Lantus) on glycemic (blood glucose) control in patients with type 2 diabetes (T2D) after hospital discharge. The authors concluded that liraglutide treatment led to improved glycemic control and greater weight loss compared to...
Read More
In a nutshell This study compared hybrid closed-loop (HCL) insulin delivery to an insulin pump or daily injections for adults with type 1 diabetes (T1D). It found that an HCL system led to better glucose control and a more positive experience of managing diabetes. Some background For many patients with T1D, managing blood glucose (sugar) levels is a...
Read More
In a nutshell This controlled trial looked at adding exenatide (Byetta) to intensive insulin treatment for patients with type 2 diabetes (T2D) who still had high blood sugar. It found that the exenatide improved blood sugar control and reduced body weight in these patients. Some background T2D is a metabolic condition in which the body does not...
Read More
In a nutshell This study compared the risk of severe hypoglycemia (dangerously low blood glucose levels) with insulin glargine-100 (Lantus) and insulin glargine-300 (Toujeo) for patients with type 1 diabetes (T1D). It found that both medications improved glucose control, and insulin glargine-300 had a lower risk of hypoglycemia. Some background T1D is...
Read More
In a nutshell This study compared two doses of dapagliflozin (Farxiga) to a placebo to determine how effective and safe they were long-term for patients with uncontrolled type 1 diabetes (T1D). The results showed that both doses were able to reduce blood glucose levels and body weight but increased the risk of ketoacidosis. Some background...
Read More
In a nutshell This study examined if non-insulin drug lixisenatide (Lyxumia) boosted treatment results from insulin glargine (Lantus) in patients with uncontrolled type 2 diabetes (T2D). Patients who received lixisenatide and glargine had improved blood glucose control and no significant increase in side effects. Some background Uncontrolled...
Read More
In a nutshell This study is looking for patients with diabetes taking insulin to test a mobile app that helps patients understand how blood glucose levels change. The main outcome that will be measured is the average blood glucose level at the beginning versus the end of the study. This study is recruiting in Boston, MA, the US. The details...
Read More
